Previous Article | Next Article ![]()
Journal of Virology, September 2007, p. 10017-10028, Vol. 81, No. 18
0022-538X/07/$08.00+0 doi:10.1128/JVI.00516-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Kentaro Fujita,
Aniko V. Paul, and
Eckard Wimmer*
Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York 11790
Received 12 March 2007/ Accepted 25 June 2007
|
|
|---|
|
|
|---|
One such cellular protein is poly(rC) binding protein 2 (PCBP2, also known as hnRNP E2 or
CP-2), an RNA binding protein with function in both translation and replication of PV RNA and possibly in RNA stability (6, 12, 13, 22, 24). PCBP2 has a strong preference for binding to poly(rC) sequences. The cellular function of PCBP2 is to form ribonucleoprotein (RNP) complexes with cellular mRNAs, which regulate mRNA stability and translation (15, 20, 23). PCBP2 contains three hnRNP K homology (KH) domains, the first and third of which mediate poly(rC) binding (9). The protein has also been shown to form homodimers (13) and to interact with other hnRNPs (4, 16).
The 5' nontranslated region (5'NTR) of PV RNA contains two highly structured regions, the cloverleaf (CL) and the internal ribosomal entry site (IRES) (Fig. 1A). The CL, which carries the 5'-terminal genome-linked protein VPg, consists of the 5'-terminal 88 nt containing stem-loops A to D (2, 13, 18, 24) (Fig. 1A and B). The C-rich region of stem-loop B has been reported to bind PCBP2 (1, 2, 13, 24) (Fig. 1A and B), while stem-loop D can specifically interact with the viral proteinase and RNA binding protein 3CDpro (1, 2, 13, 24, 28) (Fig. 1B). The formation of the ternary complex CL/PCBP/3CDpro at the 5' end is essential for RNA replication and, hence, viral proliferation. Interestingly, viral protein 3AB also forms a complex with the CL and 3CDpro, which promotes viral RNA replication (14, 36).
![]() View larger version (29K): [in a new window] |
FIG. 1. Structure of PV genomic RNA and nucleotide sequence alignment of the region between the CL and the IRES. (A) Schematic diagram of full-length PV genomes [PV1(M)] and PV-Luc replicons. The single-stranded RNA is covalently linked to the virus-encoded protein VPg at the 5' end of the 5'NTR. The 5'NTR consists of two highly structured cis-acting domains, the CL and the IRES, which are separated by a spacer region. The polyprotein (open box), consists of a structural (P1) region and two nonstructural domains (P2 and P3), specifying the replication proteins. In the replicons, the P1 domain of the polyprotein is replaced with the coding sequence of the firefly luciferase gene. A cis-replicating RNA element, cre, is located in the coding sequences of protein 2CATPase. (B) Nucleotide sequences of the PV1(M) CL and spacer and part of domain II (nt 1 to 142) that were included in the RNA probe used for the experiments. The spacer region of PV1(M) (nt 89 to 103), harboring the two C clusters (shaded areas), is compared with that of PV2(La) and PV3(Le). The closed arrows indicate the approximate PCBP binding sites, and the open arrow indicates the approximate binding site of 3CDpro. (C) Nucleotide sequence alignments of the 5' terminus of the spacer regions (nt 89 to 103) of PVs, cluster C coxsackievirus A, cluster A coxsackievirus A, cluster B coxsackievirus B (plus coxsackievirus A9), and human rhinoviruses. The boxes indicate the C-rich region that is highly conserved among the enteroviruses. M, Mahoney; La, Lancing; Le, Leon.
|
The CL and IRES elements are separated by a "spacer" sequence of 35 nt (Fig. 1A and B) to which, until recently, no special function(s) in viral proliferation had been assigned. This changed when we discovered an unexpected high degree of attenuation in CD155 transgenic mice of a PV [sPV(M)] that we had synthesized in the absence of a natural template (7). sPV(M) contained 27 mostly synonymous nucleotide exchanges designed as genetic markers (7). To our surprise, one of these genetic markers, a single nucleotide transition (A103G) mapping to the spacer region in the 5'NTR, was responsible for the strong attenuation phenotype of sPV(M) in the transgenic animals (8). Interestingly, a single A103G mutation in PV1(M) also triggered a robust temperature-sensitive phenotype in cells of neuronal origin (human SK-N-MC cells) (8). The molecular basis for the attenuation and temperature-sensitive phenotypes of the A103G virus is not yet known, but our results suggested that the defect is related to translation (8).
On the basis of these observations, we were curious about whether other signals are hidden in the spacer region that could play a role in viral proliferation, especially in RNA replication and translation. Accordingly, we have embarked upon a genetic and biochemical analysis of nucleotides in the spacer. When one compares the nucleotide sequences of the spacer regions from various entero- and rhinoviruses (Fig. 1C), two highly conserved clusters of C residues, each 3 nt long, stand out. Mutation of all six C residues to A residues had no effect on the translation of PV RNA in vitro but abolished RNA replication in HeLa cells, resulting in a dead growth phenotype. A more detailed analysis of the C-rich region revealed that a minimum of two consecutive C residues, located in the first cluster of C residues, or all three C residues from the second group, were required for virus growth. In addition, our studies showed that the efficient binding of PCBP2 to a 5'-terminal, 142-nt-long fragment of the PV RNA required the presence of at least two adjacent C residues from the C-rich region of the spacer. Interestingly, we have found that PCBP2 has little, if any, binding affinity for the CL per se (nt 1 to 88). For PCBP to function as an essential cofactor in PV genome replication, both the CL with its stem-loop B and additional C residues from the spacer region (nt 89 to 95) are required.
|
|
|---|
(i) Constructs with a substitution of nucleotides in the spacer region (nt 93 to 100). For construction of the PV1(M) derivatives listed in Fig. 2, mutagenesis was performed with the site-directed mutagenesis kit (Stratagene) with pT7PV1(M) as the template. The mutagenic oligonucleotides are described in Table 1.
![]() View larger version (19K): [in a new window] |
FIG. 2. Characterization of mutants with nucleotide substitutions in the C-rich region of the spacer. Nucleotide sequences (nt 87 to 103) of the C-rich region in mutants used in these studies are shown. Dashes represent the nucleotides conserved between WT [PV1(M)] and the mutants. Boxed sequences indicate the C-rich regions in the spacer. RNA transcripts of the WT and mutant viruses were transfected into HeLa cells, and the time of CPE was determined (see Materials and Methods). Viruses that gave no CPE after transfection were passaged one or more times. RNAs derived from viruses that emerged after transfection were reverse transcribed, and their DNA sequences were determined. The arrow indicates the location of a C residue insertion in revertant MR9. Dots indicate deletions of nucleotides in the revertants. n.r., no revertant was obtained.
|
|
View this table: [in a new window] |
TABLE 1. Oligonucleotides used for mutagenesis
|
(iii) pET21b/PCBP1. Total RNA was isolated from HeLa cells with TRIzol (Invitrogen) according to the manufacturer's instructions. PCBP1 cDNA was obtained by reverse transcription (RT)-PCR with primers 5'-CTCGAGGCTGCACCCCATGCCCTTCTC-3' and 5'-GAATTCTATGGATGCCGGTGTGACTG-3'. The PCR product was cloned into the pGEM-T Easy vector. The XhoI-EcoRI fragment of this plasmid was cloned into the XhoI/EcoRI-digested pET21b vector (Novagen).
Proteins. Purified, His-tagged PCBP1, PCBP2, and 3CDpro recombinant proteins were expressed in Escherichia coli from plasmids pET21b/PCBP1, pET21b/PCBP2 (26), and pET21b/3CDpro(3Cpro/H40A) (26), respectively. The proteins were purified by nickel column chromatography (QIAGEN).
Antibodies. Anti-PCBP2 polyclonal antiserum (33, 34) (a generous gift of Bert L. Semler, University of California, Irvine) and anti-3D monoclonal antibody (25) were used as primary antibodies for Western blot analysis.
In vitro transcription, translation, and RNA transfection. Prior to transcription by T7 RNA polymerase, pT7PV1(M) and its derivatives were linearized with EcoRI, whereas PV-Luc and its derivatives were linearized with DraI. The RNA transcripts were transfected into monolayer cultures (35-mm-diameter dishes) of HeLa R19 cells by the DEAE-dextran method, as described previously (32). Transfected cells were incubated in Dulbecco's modified Eagle medium supplemented with 2% bovine calf serum at 37°C either until a complete cytopathic effect (CPE) was observed or for at least 3 days posttransfection. After three rounds of freezing and thawing, the lysate was clarified of cell debris by low-speed centrifugation. The supernatant, containing the virus, was used for further passaging to select PV variants capable of efficient replication in HeLa R19 cells. The RNAs extracted from the viral cell lysates served as templates for RT-PCR. Isolation of viral RNA, RT-PCR, purification of PCR products, and sequencing were carried out as described previously (7). In vitro RNA translations were performed with HeLa cell S10 cytoplasmic extracts at 34°C as described previously (21).
Luciferase assay. After transfection with replicon RNA, HeLa R19 cells were incubated at 37°C in Dulbecco's modified Eagle medium (2% bovine calf serum). At 12 h posttransfection, the growth medium was removed from the dishes, and the cells were washed gently with 2 ml of phosphate-buffered saline. The HeLa cell dishes were overlaid with 300 µl of "passive" lysis buffer, supplied by Promega. The plates were rocked at room temperature for 15 min, and the lysate was transferred to a tube. Fifty microliters of luciferase assay reagent (Promega) was mixed with 20 µl of lysate, and the firefly luciferase activity was measured with an Optocomp I luminometer (MGM Instruments, Inc.).
RNA binding assay. To test the binding of proteins to PV RNA fragments, RNA pull-down assays were used, similar to what was described before by Kim et al. (17). Truncated derivatives of PV CL-spacer RNA used in the RNA binding experiments were generated by PCR amplification with oligonucleotides described in Table 2. One microgram of gel-purified PCR products was used for the generation of biotinylated RNA probes. RNA transcripts were produced by T7 RNA polymerase (Stratagene) with nucleoside triphosphates in biotinylation buffer (1 mM ATP, 1 mM CTP, 1 mM GTP, 0.65 mM UTP, and 0.35 mM biotin-16-UTP [Roche]). After 2 h of incubation at 37°C, 5 U of RNase-free DNase (Roche) was added to remove the template DNA. The transcript RNAs were purified by phenol-chloroform extraction and ethanol precipitation. RNA pull-down experiments were performed with purified recombinant proteins [500 ng of PCBP1, 500 ng of PCBP2, and 250 ng of 3CDpro(3Cpro/H40A)] or 800 µg of HeLa cell S10 cytoplasmic extracts and 4 µg of biotinylated RNAs corresponding to PV1(M) RNAs (nt 1 to 91, 1 to 92, 1 to 93, 1 to 94, 1 to 95, 1 to 100, and 1 to 142) and to mutants RNAs (nt 1 to 142), as indicated. After incubation of the RNA-protein mixture in 1 ml of incubation buffer (10 mM HEPES [pH 7.4], 1.5 mM magnesium acetate, 90 mM potassium acetate, 2.5 mM dithiothreitol, 0.05% NP-40) for 30 min at 4°C, the samples were subjected to streptavidin-agarose resin (Pierce) adsorption and further incubated for 2 h. As nonspecific competitors, 20 µg of yeast tRNA (Roche) was added to the binding mixtures. After incubation, the resin was washed four times with incubation buffer, and then the resin-bound proteins were resolved by sodium dodecyl sulfate-12.5% polyacrylamide gel electrophoresis. Western blot analysis was performed with either anti-PCBP2 polyclonal antiserum or anti-3D monoclonal antibody.
|
View this table: [in a new window] |
TABLE 2. Oligonucleotides used in making probes for RNA binding assays
|
|
|
|---|
The experiments were initiated with mutant PV cDNAs containing either C93-95A or C98-100A substitutions in the spacer region. Mutant RNA transcripts derived from these cDNAs were transfected into HeLa cells, and the time was determined at which CPEs developed. Wild-type (WT) PV1(M) RNA transcripts were transfected into cells in parallel control experiments. As shown in Fig. 2, mutant M1, containing the C93-95A substitutions, developed a CPE at 48 h postinfection, 24 h after a CPE developed with WT transcripts. The replication properties of mutant M2 transcripts (C98-100A), on the other hand, were the same as that of the WT (Fig. 2). In contrast, the replacement of all six C residues in group I and group II with A residues (M3) resulted in no CPE, even after six blind passages of the cell supernatants, an observation suggesting a lethal viral phenotype (Fig. 2). These results indicated that three of the six C residues are sufficient for viral growth but that the three C residues of group I are more important in promoting growth than those C residues of group II.
We then analyzed in more detail the function of each C in group I and group II. Since the replacement of all six C residues in groups I and II (M3) yielded a dead phenotype, we chose to change back each one of these A residues to a C, hoping to recover replication and observe the possible emergence of revertants for further analyses.
When only one A residue was changed back in group II, the variants still expressed a lethal phenotype, regardless of the position of the A residue within the cluster (Fig. 2, M4 to M6). In contrast, a single A-to-C transversion in group I led to the recovery of replication (M7 to M9) even though the CPE was greatly delayed with mutants M7 and M8 (72 h). Mutant M9 was quasi-infectious, requiring two blind passages for virus to emerge. Sequence analyses of the emerging viral genomes revealed that, compared to the parental sequences (M7 to M9), all had undergone genetic variation, as expected. Whereas in MR7 and MR8 a single A residue in group I changed back to a C residue, the MR9 variant had inserted an extra C residue (Fig. 2). Thus, in all three revertants two consecutive C residues were regenerated, an observation indicating a minimum requirement for an adjacent C pair in group I for viral growth.
In the following experiments, we changed back one additional A to a C so that two adjacent C residues, flanked by an A residue, were located in either group I or group II. These experiments directly confirmed our previous conclusion that the presence of two consecutive C residues in group I (M10) is sufficient for the production of virus. M11 also replicated with the same phenotype as the WT virus (Fig. 2). Interestingly, the position of the two C residues within group I was less efficient in M10 than in M11, as M10 RNA yielded variant MR10, in which the A at nt 95 was changed back to a C and, hence, to a C triplet (Fig. 2). In contrast, two adjacent C residues, located in group II (M13, M14), resulted in a CPE only after blind passages (Fig. 2). The progeny contained either a deletion (MR14) or a transition and a deletion (MR13). Remarkably, these changes regenerated two adjacent C residues at positions 94 and 95 (MR13, MR14), the preferred site of the C doublet in group I (Fig. 2).
We were surprised to find that the lethal phenotype of the M3 mutant can be rescued by the genetically engineered replacement of U96-97 with C residues (M12) (Fig. 2). Although M12 is quasi-infectious, we were able to isolate a revertant that contained an A-to-C transversion at nt 95 (MR12). This indicates a stringent requirement for a C residue at this position. The last two mutants in this set contained three A residues in either group I or group II and another A in the center of the second group, disrupting the C triplet (M15, M16, Fig. 2). The MR15 variant derived from M15 emerged after a delayed CPE. It contained the reversion A94C (MR15) that reestablished the C triplet in group I. The M16 construct was quasi-infectious and required three blind passages to yield MR16. This variant had acquired two adjacent C residues at positions 95 and 96 (MR16) (Fig. 2).
The major conclusions of these mutational analyses are that the C-rich region of the spacer has a function in viral growth and that the C residues in group I are more important than those of group II. Two adjacent C residues (C94 and C95) in group I of the spacer are sufficient to support what appears to be normal WT viral growth under the conditions of the experiment, and the position of these two C residues is preferred over position C93 C94. On the other hand, the presence of such two C residues in group II results in highly impaired growth phenotypes.
Replacement of the six C residues with A residues in the spacer has no effect on translation, but it leads to a defect in RNA replication. As we have discussed above, the replacement of the two triplets of C residues with A residues in the spacer (M3) abolishes virus growth. To determine at which stage of the viral life cycle these mutations exert their effect, we have carried out in vitro translations in HeLa cell extracts of full-length WT and mutant PV RNAs. As shown on Fig. 3A, translation of M3 mutant RNA and the processing of the resulting polyprotein are essentially the same (lane 4) as those of WT PV RNA (lane 1). Similarly, the A93-95 (M1) and A98-100 (M2) mutant RNAs exhibit the same translation and processing profiles as the WT RNA (Fig. 3A, lanes 2 and 3). In vitro translations in HeLa cell extract are excellent indicators of the quality of the viral RNA template, as well as of translation and of proteolytic processing (21).
![]() View larger version (31K): [in a new window] |
FIG. 3. Analysis of translation and replication of WT and mutant PV RNAs. (A) In vitro translation of full-length transcript RNAs derived from PV1(M) and its derivates M1 (C93-95A), M2 (C98-100A), and M3 (C93-95, 98-100A). Reaction mixtures containing in vitro-transcribed mutant and WT PV RNAs (250 ng) were translated in a HeLa cell S10 cytoplasmic extract (see Materials and Methods). (B) Firefly luciferase activities of various PV-Luc replicons with or without (w/o) 2 mM GnHCl. Transfection of WT and mutant RNAs and the measurement of luciferase activities are described in Materials and Methods.
|
Mutations in the C-rich region of the spacer affect the binding of PCBP to the 5'-terminal 142 nt of PV RNA. It has been reported that the cellular RNA binding protein PCBP2 binds to the PV CL (1, 2, 13, 24), where the predominant site of contact is believed to be a triplet of three C residues in stem-loop B (C23-25) (13, 24; Fig. 1B). The CL structure itself comprises nt 1 to 88 (Fig. 1B). However, previous analyses of PCBP-CL binding have always involved 5'-terminal RNA fragments that were longer than 88 nt (usually 108 nt long) and included the C-rich region of the spacer analyzed here (2, 11, 13, 24, 34). Since our studies implicated the C-rich region contained in the spacer in RNA replication and viral growth and because PCBP2 has an affinity for C-rich sequences, we were interested in determining whether the group I and/or group II C residues participate in PCBP2 binding. To test this possibility, we used a pull-down assay described by Kim et al. (17), in which biotinylated RNA, after binding to protein, is adsorbed to streptavidin-agarose resin, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analyses of the RNA-protein complexes. The RNA probes were transcript RNAs containing sequences of the CL (nt 1 to 88), of the CL plus various lengths of the spacer, or of the CL plus the spacer and a short segment of domain II (nt 1 to 142). The source of proteins was either a HeLa cell extract or purified PCBP2 or PCBP1.
Figure 4A shows that in a pull-down assay with HeLa cell extracts and the WT RNA transcript (nt 1 to 142), two major bands and one minor band of PCBP were detected with anti-PCBP2 polyclonal antiserum (lane 1), an observation illustrating our probe's affinity for different PCBP subtypes. Walter et al. have previously shown that one of these PCBP bands is a doublet (33, 34). We obtained the same results with RNA probes containing either the M1 or the M2 mutation (Fig. 4A, lanes 3 and 4, respectively). In contrast, no PCBP binding was observed when all six C residues in group I and group II were replaced with A residues (M3), an observation indicating the importance of the C-rich region of the spacer in PCBP binding (Fig. 4A, lane 5), regardless of the presence of the C residues in stem-loop B of the CL. However, no PCBP binding was detected with the 142-nt RNA probe that contained a deletion of 4 nt in stem-loop B of the CL, which was previously shown to be required for the binding of this protein (Fig. 4A, lane 2) (13, 24). These results demonstrate that PCBP binding to the CL requires both stem-loop B of the CL and either the group I or group II C residues of the C-rich region from the spacer.
![]() View larger version (19K): [in a new window] |
FIG. 4. Analysis of PCBP binding to a 142-nt-long RNA fragment derived from the 5' terminus of PV RNA. PCBP binding to WT and mutant RNA probes (nt 1 to 142) was analyzed with an RNA pull-down assay followed by Western analysis with anti-PCBP2 polyclonal antiserum (see Materials and Methods). (A) PCBP binding to WT and mutant RNA probes was measured with HeLa cell extracts. Nucleotides 23 to 26 (CCCA) were deleted from stem-loop B of the PV CL (Del. CL SL-b) (12, 13). (B) Binding of purified PCBP1 and PCBP2 to WT and mutant RNA probes (nt 1 to 142) (lanes 3 to 7). The binding of purified PCBP1 (500 ng) and PCBP2 (500 ng) to WT and mutant RNA probes was measured as described in Materials and Methods. Western blot analysis of 500 ng of PCBP1 and PCBP2 with anti-PCBP2 polyclonal antiserum (lanes 1 and 2). (C) Binding of PCBP2 to WT and mutant RNA probes in the absence and presence of 3CDpro. The binding of purified PCBP2 (500 ng) with or without (w/o) purified 3CDpro (250 ng) to WT and mutant RNA probes was measured (see Materials and Methods). Immunoblot analysis was performed by using either anti-PCBP2 polyclonal antiserum or anti-3D monoclonal antibody (Ab). Symbols: –, no protein added; +, protein added. (D) Binding of PCBP to WT and mutant RNA probes. The RNA binding experiments were performed with HeLa cell S10 cytoplasmic extracts and WT and mutant RNA probes (nt 1 to 142).
|
It has been suggested previously that the interaction of PCBP2 with the extended CL (nt 1 to 108) in vitro is stimulated by the addition of viral proteinase 3CDpro, an RNA binding protein (11). The two proteins are believed to form a complex in which PCBP2 binds to stem-loop B and 3CDpro to stem-loop D of the CL (1, 2, 13, 24, 28). We have confirmed these results with the WT probe (nt 1 to 142), purified PCBP2, and purified 3CDpro (Fig. 4C, compare lane 1 with lane 2), where the presence of 3CDpro in the RNA-protein complex was demonstrated with anti-3Dpol antibodies (Fig. 4C, lane 2). In contrast, our M3 mutant probe did not bind PCBP2 either in the absence or in the presence of 3CDpro (Fig. 4C, compare lane 1 with lanes 3 and 4). Notably, 3CDpro alone did bind to the M3 probe (Fig. 4C, lane 4). These results indicate that the C-rich region of the spacer is required for the binding of PCBP2 but not of 3CDpro and that the addition of 3CDpro to PCBP2 does not rescue the effect of the M3 mutations.
To analyze in more detail the importance of the group I and group II C residues in the binding of PCBP, we tested all of our spacer mutants with the RNA pull-down assay and the same RNA probe (nt 1 to 142). Our results indicate that the mutants can be divided into two groups. The larger group (13 out of the 16 tested) shows a very good correlation between the growth phenotype of the mutants (Fig. 2) and their ability to bind PCBP (Fig. 4D). Specifically, the mutations leading to a lethal phenotype (M3 to M6) allow no detectable PCBP binding when present in the RNA probe (Fig. 4D, lanes 2 to 5). On the other hand, M11, which expresses a normal growth phenotype (Fig. 2), binds PCBP like the WT (Fig. 4D, compare lane 1 and lane 10). The mutants that possess a quasi-infectious growth phenotype (M7 to M10, M15, and M16) exhibit detectable but weaker-than-normal binding of the protein to the probe (Fig. 4D, compare lane 1 with lanes 6 to 9 and lanes 14 and 15).
Unexpectedly, a second and smaller group of mutants (M12 to M14) exhibited efficient binding of PCBP (Fig. 4D, compare lane 1 with lanes 11 to 13) but they were quasi-infectious, that is, severely impaired in growth (Fig. 2). Therefore, these results suggested the possibility that although these mutant RNAs were able to bind PCBP, this interaction did not promote efficient RNA replication. To test this hypothesis, we analyzed mutant M14 in the background of a luciferase replicon (Fig. 3B). As expected, the mutation reduced RNA replication to levels below detection by this assay (Fig. 3B, lane 5) but its variant MR14 that was isolated after three blind passages (Fig. 2) fully regained the ability to replicate (Fig. 3B, lane 6). The binding of PCBP to MR14 RNA was the same as that to the M14 RNA (data not shown). A closer examination of M14 RNA reveals the presence of two adjacent C residues located in the group II position. In the corresponding revertant, MR14, these two C residues have been moved into the group I position by deletion of 5 nt. It appears, therefore, that two adjacent C residues in group II at nt 99 and 100 (M14) do allow PCBP binding to the 5'-terminal fragment but this binding is inadequate for efficient RNA replication to occur. A very similar relationship exists between M13 and its variant MR13. Here, the virus introduced a C residue at position 97 by transition and then deleted 3 nt to move two C residues into the group I position (MR13, Fig. 2). A triplet of C residues is more favorable for PCBP binding, and hence, the position effect is less stringent. Therefore, the quasi-infectious M12 RNA introduced a C residue into nt 95 by transversion, thereby generating a C triplet (MR12, Fig. 2), which allows adequate RNA replication.
These data led us to conclude that there is an important functional difference between the C residues of groups I and II. Although two adjacent C residues in either group I or group II are sufficient for binding of PCBP, these same C residues in group II are not able to promote efficient RNA replication, hence the quasi-infectious nature of the viral mutant RNAs. In addition, data derived from our genetic analyses and biochemical PCBP binding studies suggest that, in vivo, the PCBP binding site that is preferred for RNA replication is located in group I, particularly at nucleotides C94 and C95. As we have noted above, however, a full triplet of C residues weakens the position effect. Accordingly, the single C triplet in group II (M1) is nearly as efficient in both PCBP binding and RNA replication as the single triplet of C residues in group I (M2). It is possible that long-term passage of M1 would regenerate adjacent C residues in the group I position. This experiment, however, has not been carried out.
The binding of PCBP2 to the CL requires nucleotides from the C-rich region of the spacer. Since our results have indicated the importance of both stem-loop B of the CL and the C-rich region of the spacer in PCBP binding to the PV RNA 5' terminus (nt 1 to 142), we were interested in determining the minimal length of the spacer RNA that is required for binding. Although the actual length of the CL is only 88 nt, previous studies, which showed PCBP binding to the CL, always used a 108-nt-long RNA segment (2, 11, 13, 24, 34). With HeLa cell extracts and 5'-terminal RNA fragments 91, 92, or 93 nt long, we observed no detectable binding of the protein to the probe (Fig. 5, lanes 1, 2 and 3, respectively). In contrast, normal PCBP binding was observed with RNAs 95 nt long or longer, which contained at least the first triplet of C residues (C93-95) (Fig. 5, lanes 5 and 6). This finding shows that 95 nt are required for optimal PCBP binding, although weak binding can already be detected with a 94-nt-long probe.
![]() View larger version (9K): [in a new window] |
FIG. 5. PCBP binding to the CL requires sequences from the spacer region. PCBP binding was analyzed with WT RNA probes of different lengths (nt 1 to 91 to nt 1 to 100) and HeLa cell extracts. Western blotting analysis was performed with anti-PCBP2 polyclonal antiserum (see Materials and Methods). w/o, without.
|
|
|
|---|
Genetics of the C-rich domain in the spacer region. The construction and analyses of 16 different genetic variants in the C-rich region of the spacer have allowed us to divide the mutant genomes into three phenotypes, replication competent, quasi-infectious, and dead. Specifically, our results suggest that the presence of three consecutive C residues in either group I (M2) or group II (M1) of the spacer is sufficient for the production of virus with growth properties similar, but not identical, to those of the WT virus. A comparison of the growth phenotypes of M1 and M2 hinted at the possibility of a position effect of the C triplet in replication (Fig. 2).
RNA genomes with only a CC duplet in the group I position (M10, M11) replicated either immediately with WT kinetics (M11) or proceeded to rapidly exchange an A residue for a C residue in group I, thereby creating a C triplet (MR10). In stark contrast, replication of genomes M13 and M14 with two consecutive C residues in group II is severely obstructed (quasi-infectious). Significantly, variants isolated from M13 or M14 RNA-infected cells managed to establish two adjacent C residues in group I (MR13 and M14, respectively). This position effect is also apparent in mutants that were constructed to contain only a single C residue in either group I or group II (M4 to M9). Whereas mutant genomes M4 to M6 expressed a dead phenotype, quasi-infectious genomes M7 to M9 allowed sufficient replication for the selection of variants with a C duplet in group I (MR7 to MR9).
These data support a rule that, if presented with a choice, the virus strongly prefers C triplets or C duplets in the group I position rather than in the group II position. The rule is slightly violated in MR12 and MR16, where the duplet is moved to the 95-96 position, 1 nt out of group I (Fig. 2). We have not yet performed long-term passage experiments with the variants listed in Fig. 2. But we predict that eventually new variants would emerge from cells infected with MR12 or MR16 carrying a CC duplet in the group I position.
It should be noted that drastic sequence changes in the spacer downstream of the C clusters do not appear to significantly influence PV replication. For example, the PV cre element (63 nt) has been inserted into the spacer at nt 103, where it can rescue a lethal mutation in endogenous 2C(cre) (Fig. 1A) (37). PV with cre in the spacer (which is temperature sensitive, just like the A103G virus) has been found to be highly attenuated in CD155 transgenic mice; it has recently been successfully used to cure immunocompetent CD155 transgenic mice carrying a lethal neuroblastoma (30).
Effect of spacer mutagenesis on translation and RNA replication. To determine at which stage of viral growth the mutations exert their effect, we have first compared the translation of WT and mutant PV RNAs in HeLa cell extracts. There were no significant differences in either the translation efficiency or the processing of the polypeptides between the WT and mutant RNAs (Fig. 3A), an observation suggesting that the translation of these viral constructs that we consider representative of all mutants, is normal. We next examined the effect of the mutations directly on RNA replication in HeLa cells by using a luciferase replicon (19). Our results clearly indicated that the mutations in the C-rich region of the spacer affect RNA replication. The lethal M3 mutation caused a total block in RNA replication, and the M1 mutation caused a retardation of RNA replication when the luciferase signal was assayed at 6 h posttransfection. On the other hand, the viable M2 mutant exhibited luciferase activities comparable to those of the WT.
Binding of the CL-spacer sequence to PCBP. The discovery of PCBP as a cellular RNA binding protein involved in two major steps in PV proliferation has advanced our understanding of the interplay between PV genetic elements and host factors. PCBP plays a decisive role in the regulation of IRES-mediated, cap-independent initiation of translation of the virus genome (5, 6, 13, 33). In this process, PCBP binds to domain IV of the IRES (Fig. 1A) and, as recently reported, it collaborates in translation regulation with SRp20, another cellular protein and a member of the SR protein family (4).
In addition to IRES binding, PCBP also has an affinity for the C-rich region in stem-loop B of the 5'-terminal CL (1, 2, 13, 34). However, we report here that this affinity is not sufficient to mediate binding of the cellular protein to the PV genome in this region. Rather, an additional C-rich site, located in the spacer region just downstream of the CL, is required for PCBP binding, regardless of the isotype of the cellular RNA binding protein (PCBP1 or PCBP2). Binding of PCBP to this second C-rich site is essential for viral proliferation.
Specifically, we have tested spacer mutants described above to determine the effects of different nucleotide changes (C to A) on PCBP binding. These experiments revealed that the presence of only a single C in group I and group II resulted in either poor binding of PCBP or no detectable binding, respectively. In contrast, the presence of two or three consecutive C residues in either group I or group II was found to be sufficient for efficient PCBP binding. When the PCBP binding and viral proliferation abilities of the mutants were compared, they could be divided into two groups. With the larger group of mutants (M1 to -11, M15, and M16), there was a very good correlation between PCBP binding and viral growth. A smaller group of mutants (M12 to M14), on the other hand, interacted with PCBP very efficiently but exhibited a highly impaired growth phenotype. These results suggested that the PCBP/RNA complex formed with these mutants functioned only poorly in RNA replication. We confirmed this hypothesis by using one of these mutants (M14) with a luciferase replicon. The mutant was found to be defective in RNA replication as assayed by the luciferase signal (the mutant is quasi-infectious, and it required three blind passages for recovery of the viable variant MR14; Fig. 2), while its progeny virus MR14 regained the ability to replicate.
As mentioned, it has been previously shown by different investigators that PCBP2 binds to stem-loop B of the CL, most likely to the triplet of C residues at nt 23 to 25 (13, 24). Although the CL consists of only 88 nt, the RNA probes used in the previous studies of PCBP binding to CL were always 108 nt long (nt 1 to 108) (2, 11, 13, 24, 34). However, when we tested the CL structure alone (nt 1 to 91), no PCBP binding was observed (Fig. 5, lane 5). For efficient binding to occur, a minimum length of 95 nt from the 5' terminus is required (Fig. 5, lane 2). On the other hand, our probe of 142 nt failed to bind PCBP when the binding site in stem-loop B of the CL was deleted (Fig. 4A, lane 2). These data strongly suggest that the binding sites in both the CL and the spacer are required for PCBP binding and that they collaborate together.
PCBP, a polypeptide of 36 kDa, contains three hnRNP KH RNA binding domains. Experimental evidence suggests that only KH1 is essential for RNA replication (and translation), while the KH2 and KH3 domains are dispensable for initiation of RNA synthesis to occur (29, 34). The requirement for two intact PCBP binding sites in the CL and the adjacent spacer and the robust "position effect" of the PCBP binding site downstream of the CL indicate a spacing restriction for the protein-RNA interaction. For this reason, we consider it unlikely that this spacer function could be transposed to another locus in the genome (e.g., into the spacer between the IRES and the open reading frame) while the original sequence downstream of the CL would be inactivated for PCBP binding. However, such experiments remain to be carried out.
Since it was previously demonstrated that PCBP forms an RNP complex with the CL and protein 3CDpro (1, 2, 24), we examined the effect of the spacer mutations on the binding of 3CDpro. As expected, we observed an enhancement of PCBP binding in the presence of 3CDpro. However, a spacer mutation that ablated PCBP binding had no effect on the interaction between 3CDpro and the 142-nt-long RNA. The three-dimensional structure of the enterovirus CL is unknown. It is likely, however, that an interaction of PCBP, of 3CDpro, or of PCBP/3CDpro changes the three-dimensional structure of the CL in a specific manner. The details of the interactions among proteins, the CL, and the spacer (stoichiometry, succession of binding) remain to be elucidated.
Recently, Bailey and Tapprich have presented a refined secondary structure of the 5'-terminal sequence (CL-spacer-IRES) of coxsackievirus B3 (3). Although a long-range pairing interaction between sequences of domain II and domain V has been uncovered, the spacer region between the CL and the first base-paired region, containing the C region, remained available for PCBP binding.
PV, just like all RNA viruses, replicates under conditions of genetic austerity because it has chosen to exist without proofreading and editing functions during RNA replication, and hence, its genome is small (35). Since the PV genome is densely packed with genetic information, we should not be surprised that the sequence between the CL and the IRES has an essential function(s) in viral proliferation. In this regard, the term "spacer" for this sequence is a misnomer.
Hidemi Toyoda was the recipient of a scholarship from the Pediatric Oncology Research Foundation (Japan). This work was supported by NIH grant AI5122.
Published ahead of print on 3 July 2007. ![]()
Present address: Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016. ![]()
Present address: Laboratory Animal Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»